Male hormone-interfering drugs and meningioma development
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Male hormone-interfering drugs and meningioma development. / Giraldi, Laura; Hansen, Jørgen Vinsløv; Wohlfahrt, Jan; Melbye, Mads; Fugleholm, Kåre; Munch, Tina Nørgaard.
In: Neuro-Oncology Advances, Vol. 1, No. 1, vdz046, 2019.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Male hormone-interfering drugs and meningioma development
AU - Giraldi, Laura
AU - Hansen, Jørgen Vinsløv
AU - Wohlfahrt, Jan
AU - Melbye, Mads
AU - Fugleholm, Kåre
AU - Munch, Tina Nørgaard
PY - 2019
Y1 - 2019
N2 - BackgroundExtremely strong associations between male hormone-interfering drugs and meningiomas have been reported in two previous studies, but these findings are limited by small size of the study populations and possibly by surveillance- and selection bias. Thus, such possible and indeed very interesting association must be investigated in a large, unselected cohort. Accordingly, the aim of this study was to determine whether patients exposed to male hormone-interfering drugs had a higher risk of meningioma development in a nationwide cohort study.MethodsA retrospective Danish nationwide cohort study with follow-up from January 1, 1996 to December 31, 2016. Exposure was use of male hormone-interfering drugs (5-α-reductase-inhibitors, luteinizing hormone-releasing hormone agonist, steroidal antiandrogen, and nonsteroidal antiandrogen). Hazard ratio of first-time diagnosis of meningioma according to drug use was estimated using Cox proportional hazards model with adjustment for age and birth year.ResultsThe cohort included 244,696 men of which 64,047 had used male hormone-interfering drugs. Overall 444 meningiomas occurred during follow-up. No significant association was observed between use of male hormone-interfering drugs and the occurrence of meningioma (hazard ratio 1.02, 95% confidence interval 0.82–1.27). Similar results were observed 0–1, 2–4, and 5+ years after first use. In explorative analyses, no elevated risk association was observed for specific drugs (5-α-reductase-inhibitors, luteinizing hormone-releasing hormone agonist, steroidal antiandrogen, and nonsteroidal antiandrogen).ConclusionAs opposed to previous studies, we found no evidence of an increased risk of meningioma in men treated with male hormone-interfering drugs.
AB - BackgroundExtremely strong associations between male hormone-interfering drugs and meningiomas have been reported in two previous studies, but these findings are limited by small size of the study populations and possibly by surveillance- and selection bias. Thus, such possible and indeed very interesting association must be investigated in a large, unselected cohort. Accordingly, the aim of this study was to determine whether patients exposed to male hormone-interfering drugs had a higher risk of meningioma development in a nationwide cohort study.MethodsA retrospective Danish nationwide cohort study with follow-up from January 1, 1996 to December 31, 2016. Exposure was use of male hormone-interfering drugs (5-α-reductase-inhibitors, luteinizing hormone-releasing hormone agonist, steroidal antiandrogen, and nonsteroidal antiandrogen). Hazard ratio of first-time diagnosis of meningioma according to drug use was estimated using Cox proportional hazards model with adjustment for age and birth year.ResultsThe cohort included 244,696 men of which 64,047 had used male hormone-interfering drugs. Overall 444 meningiomas occurred during follow-up. No significant association was observed between use of male hormone-interfering drugs and the occurrence of meningioma (hazard ratio 1.02, 95% confidence interval 0.82–1.27). Similar results were observed 0–1, 2–4, and 5+ years after first use. In explorative analyses, no elevated risk association was observed for specific drugs (5-α-reductase-inhibitors, luteinizing hormone-releasing hormone agonist, steroidal antiandrogen, and nonsteroidal antiandrogen).ConclusionAs opposed to previous studies, we found no evidence of an increased risk of meningioma in men treated with male hormone-interfering drugs.
U2 - 10.1093/noajnl/vdz046
DO - 10.1093/noajnl/vdz046
M3 - Journal article
C2 - 32642670
VL - 1
JO - Neuro-Oncology Advances
JF - Neuro-Oncology Advances
SN - 2632-2498
IS - 1
M1 - vdz046
ER -
ID: 241384523